Chronic Myeloid Leukemia In Chronic Phase clinical trials

Explore recruiting chronic myeloid leukemia in chronic phase clinical trials.

Recruiting chronic myeloid leukemia in chronic phase studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Myeloid Leukemia In Chronic Phase trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors.

Hungary, France, Netherlands, Germany, Greece, Poland +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase II, multi-center, prospective, open-label study of Asciminib in patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or accelerated Phase (CML-AP) with T315I mutation who are resistant, intolerant or ineligible to ponatinib (ASC4TARGET)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation

Spain, France, Germany, Poland, Italy, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Chronic Myeloid Leukemia In Chronic Phase trials by city

Chronic Myeloid Leukemia In Chronic Phase in Toronto Chronic Myeloid Leukemia In Chronic Phase in Vancouver Chronic Myeloid Leukemia In Chronic Phase in Montreal Chronic Myeloid Leukemia In Chronic Phase in Calgary Chronic Myeloid Leukemia In Chronic Phase in Edmonton Chronic Myeloid Leukemia In Chronic Phase in Ottawa Chronic Myeloid Leukemia In Chronic Phase in Winnipeg Chronic Myeloid Leukemia In Chronic Phase in Quebec City Chronic Myeloid Leukemia In Chronic Phase in Hamilton Chronic Myeloid Leukemia In Chronic Phase in Kitchener Chronic Myeloid Leukemia In Chronic Phase in London Chronic Myeloid Leukemia In Chronic Phase in Halifax Chronic Myeloid Leukemia In Chronic Phase in New York Chronic Myeloid Leukemia In Chronic Phase in Los Angeles Chronic Myeloid Leukemia In Chronic Phase in Chicago Chronic Myeloid Leukemia In Chronic Phase in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease